HENDERSON, NV / ACCESSWIRE / December 17, 2018 / Low back pain is the leading cause of disability in the world and the second most cause of disability in the United States. Degenerative disc disease is one of the most common causes of back pain, affecting more than 3 million people in the US per year. Is estimated that the cost for back pain range from to "at least $50 billion per year" (American Chiropractic Association) to $86 billion per year (WebMD) and to more than $200 billion dollars per year (American Academy of Orthopaedic Surgeons). Moreover, in 2012 alone, a study reported by health economists at John Hopkins University showed that the annual cost of chronic pain was as high as $635 billion a year, which was more than the yearly costs for cancer, heart disease and diabetes. It is quite difficult to estimate the cost due to the many factors that play into the real and associated costs. Regardless of its exact amount, it is an extremely large cost that significantly affects the average American.
Back pain can also occur with a condition called degenerative disc disease, a condition where one or more discs in the spine lose their strength (due to the deterioration or breaking down of one or more of the discs between the vertebrae of the spinal column), which leads to pain. There are various current treatments for chronic lower back pain and disc degeneration, including opioid pain relievers, steroid injections, and physical therapy. However, these methods simply manage pain and ignore the root causes of the problem. According to the Centers for Disease Control and Prevention (CDC), "millions of Americans are treated with prescription opioids for chronic pain and primary care providers are concerned about patient addiction and report insufficient training in prescribing opioids. CDC continues, "Opioids (including prescription opioids, heroin, and fentanyl) killed more than 42,000 people in 2016, more than any year on record. 40% of all opioid overdose deaths involve a prescription opioid. In 2016, prescribing rates continue to remain high in areas across the country."
During this crucial time of finding a solution for one of the current major health issues in the United States, including low chronic pain or degenerative disc condition and an opioid overdose epidemic, comes Biorestorative Therapies (BRTX) (Market cap: $6.942M, Share price: $0.71). It is a company that offers a novel product- BRTX-100- to treat damaged, degenerating discs, and is anticipated to be safer, cheaper, and more effective upon a single treatment. Specifically, BRTX-100 is an autologous stem cell product that uses your own stem cells that are harvested, cultured, and then injected directly into the affected disc to start the repair process. BRTX-100 has shown positive results in preclinical human studies. BioRestorative has an open IND (Investigational New Drug) and has agreed with the FDA on a Phase 2 trial protocol that is targeted to start Q1 of 2019.
Biorestorative Therapies' newly appointed Executive VP and Chief Strategy Officer, Lance Alstodt, with extensive professional experience in both business development and capital markets along with extensive knowledge within medical technology and biopharma, stated that "the company looks forward to advancing the Phase 2 trial for BRTX-100, an autologous therapy designed for the non-surgical treatment of painful lumbosacral disc disorders. This therapy addresses a significant and underserved multi-billion-dollar market, and provides an attractive alternative to traditional spine surgery."
Another biotechnology company that treats pain and inflammations and deals with chronic pain management is CARA Therapeutics (CARA) (Market Cap: $554.228M, Share price: $14.05). Cara Therapeutics is a clinical-stage biotechnology company located in Stamford, CT focused on developing and commercializing new chemical entities designed to fundamentally change the way acute pain, chronic pain and pruritus are managed. They intend to achieve this by developing new products that selectively target the body's peripheral kappa opioid receptors. On October 23, 2018, CARA appointed Joana Goncalves, M.D., as Chief Medical Officer (CMO).
A company that also uses non-drug treatment approaches for chronic pain is Abbott Laboratories (ABT) (Market cap: $124.278B, Share price: $70.76). Abbott has created technologies that let patients manage their own treatments. Abbott's neuromodulation business and the company's products aim to relieve pain. ABT addressing chronic pain centers on Dorsal Root Ganglion (DRG) stimulation. DRG therapy systems involve electrical leads inserted into the body that are then attached to a battery implanted inside the body. Abbott's Proclaim platform provides a unique interface that puts patients in charge of how much stimulation they're getting.
If surgery is still the patient's preferred method, Stryker Corporation (SYK) (Market cap: $62.325B, Share price: $166.56) offers products such as intuitive software and platforms that are designed to optimize the spinal surgery experience. They've designed a variety of retractors as well as manual and power tools to help navigate through spinal access and decompression. Their Discmonitor Discography Probe and Dekompressor Disc Removal System were developed to help patients with symptomatic discs.
Collegium Pharmaceutical (COLL) (Market cap: $603.11M, Share price: $18.14) claims to offer responsible pain management by developing and commercializing innovative and differentiated products for people suffering from pain. Their products include Xtampza ER (oxycodone), which is designed to provide adequate pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. The company admits that abuse of Xtampza ER is still possible, but stated FDA has determined that the product has abuse-deterrent properties.
Each company offers a solution to helping patients with their painful condition. Investors may want to think about the company that doesn't apply methods which simply manage the pain and ignore the root causes of the problem. The nation has to decrease its drug abuse cases and start looking for a company that offers a non-surgical product that is anticipated to be safer, cheaper, and more effective upon a single treatment.
This article was written by Regal Consulting, LLC ("Regal Consulting"). Regal Consulting has agreed to receive a $90,000 convertible note with the issuer for 90 days of service dated 7/10/18. Regal Consulting has signed an amendment to the agreement dated 7/10/18, to extend the agreement and provide additional services for an additional $80,000 convertible note with the issuer. Regal Consulting has signed a second amendment to add additional services for an additional $90,000 convertible note. All payments were made directly by BioRestorative Therapies, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspeculators.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. BRTX was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.
http://www.regalconsultingllc.com/full legal disclaimer/
Microspeculators.com Full Legal Disclaimer Click Here.
Company Name: Microcap Speculators
Contact Person: Media Manager
Country: United States
SOURCE: ACR Communications, LLC